Photodynamic therapy in combination with intravitreal ziv-aflibercept and aflibercept injection in patients with chronic or repeatedly recurrent acute central serous chorioretinopathy: a single-center retrospective study
Open Access
- 1 July 2018
- journal article
- research article
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 12, 1301-1309
Abstract
Purpose: The objective of the study was to assess the effect of off-label photodynamic therapy (PDT) in combination with intravitreal off-label ziv-aflibercept or off-label aflibercept injection in patients with chronic or repeatedly recurrent acute central serous chorioretinopathy (CSC). Patients and methods: Changes in best corrected visual acuity (BCVA) and subfoveal subretinal fluid (sSRF) and maximum subretinal fluid (mSRF) were retrospectively analyzed in a single-center cohort study of 17 patients (18 eyes) with persistent subretinal fluid for more than 3 months of duration of CSC. Treatment efficacy was measured between injection and PDT at 30±15 days, 90±15 days and 180±30 days after PDT. Results: Significant reduction of sSRF and mSRF was shown after therapy with ziv-aflibercept and aflibercept combined with PDT (pp=0.065). One case of allergic reaction after fluorescein angiography and one case of ophthalmic migraine after ziv-aflibercept injection were documented. One case of reversible vision loss occurred during 6 months after combination therapy. No other adverse events or side effects were reported. Conclusion: Combination therapy of ziv-aflibercept and aflibercept with PDT seems to be beneficial, even in cases of chronic or repeatedly recurrent acute CSC. This includes cases of CSC resistant to or recurrent after medical treatment, PDT alone or therapy with anti-vascular endothelial growth factor alone.Keywords
This publication has 44 references indexed in Scilit:
- Chronic central serous chorioretinopathy: long-term follow-up and vision-related quality of lifeClinical Ophthalmology, 2016
- Choroidal Thickness Changes After Intravitreal Antivascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration: Ranibizumab Versus AfliberceptJournal of Ocular Pharmacology and Therapeutics, 2015
- Change in choroidal thickness after intravitreal aflibercept in pretreated and treatment-naive eyes for neovascular age-related macular degenerationBritish Journal of Ophthalmology, 2015
- Photodynamic therapy for central serous chorioretinopathyEye, 2014
- A Randomized Pilot Study of Low-Fluence Photodynamic Therapy Versus Intravitreal Ranibizumab for Chronic Central Serous ChorioretinopathyAmerican Journal of Ophthalmology, 2011
- Factors Influencing the Visual Acuity of Chronic Central Serous ChorioretinopathyKorean Journal of Ophthalmology, 2011
- Intravitreal Bevacizumab in Treatment of Idiopathic Persistent Central Serous Chorioretinopathy: A Prospective, Controlled Clinical StudyCurrent Eye Research, 2010
- Standard-Fluence versus Low-Fluence Photodynamic Therapy in Chronic Central Serous Chorioretinopathy: A Nonrandomized Clinical TrialAmerican Journal of Ophthalmology, 2010
- Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot studyBritish Journal of Ophthalmology, 2006
- VEGF-Trap: A VEGF blocker with potent antitumor effectsProceedings of the National Academy of Sciences, 2002